Dasatinib Dose Optimization With Weekend Drug Holiday for Improved Tolerability in Chronic Myeloid Leukemia (DasaHIT): A German Chronic Myeloid Leukemia Alliance Randomized Trial
Year: 2026
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: PURPOSE To compare standard-dose dasatinib 100 mg once daily with reduced-dose using a weekend drug holiday to improve tolerability for patients with chronic myeloid leukemia (CML). PATIENTS AND METHODS Patients with chronic phase CML (CP-CML) were randomly assigned to either receive standard-of-care dasatinib 100 mg once daily or an intermittent dasatinib schedule (5 days on, 2 days [weekend] off) in a prospective multicenter phase III trial. Achievement of major molecular remission (MMR) at 24 months and a newly developed cumulative toxicity score were coprimary end points. RESULTS Of 289 eligible patients, 147 were assigned to standard-of-care dasatinib and 142 to intermittent dosing. Eighty percent of patients received first-line treatment (n = 232). In the standard arm, 105 of 130 patients (81% [95% CI, 74% to 88%) achieved MMR at 24 months compared with 101 of 130 patients (78% [95% CI, 71% to 85%]) in the experimental arm resulting in noninferiority within the prespecified noninferiority margin of 15% ( P = .009). Among second- or later-line patients, MMR at 24 months was 24% lower, failing noninferiority. Comparison of grade 2-4 toxicities revealed no significant difference between the treatment arms. However, a post hoc analysis of toxicities of special interest (pleural effusion/pericardial effusion) showed 21 of 130 patients (16%) in the standard arm versus 10 of 125 (8%) patients in the experimental arm ( P = .0464). Consistently, health-related quality of life improved mainly in first-line patients, with more favorable outcomes in the experimental arm. CONCLUSION Intermittent dasatinib dosing with weekend treatment holidays in patients with CP-CML is noninferior to continuous dosing with respect to MMR at 24 months, at least in the first-line setting. The incidence of pleural or pericardial effusion appears to be reduced compared with standard-of-care continuous dosing.
Source: Journal of Clinical Oncology
DOI: 10.1200/jco-26-00899
Authors: Paul La Rosée, Philipp Ernst, Christian Fabisch, Annamaria Brioli, Dominik Wolf, Lino L. Teichmann, Ludwig Fischer von Weikersthal, Susanne Saussele, Theresa Früh, Frank Stegelmann, Cornelius F. Waller, Bernd Hertenstein, Tim H. Brümmendorf, Andreas Burchert, Jenny Rinke, Ali Albeer, Thomas Ernst, Markus Pfirrmann, Andreas Hochhaus, on behalf of the German CML Study Group
Institutions: Jena University Hospital, Schwarzwald-Baar Klinikum, Medizinische Hochschule Hannover, Innsbruck Medical University, Universität Innsbruck, Tyrolean Cancer Research Institute, University Hospital Bonn, Centrum für Integrierte Onkologie, University Medical Centre Mannheim, University Hospital Ulm, University of Freiburg, University Medical Center Freiburg, Klinikum Bremen-Mitte, Universitätsklinikum Aachen, Philipps University of Marburg, Universitätsklinikum Gießen und Marburg, Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universität München
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7225995239
